Latest Period
Q1 2026
Security Snapshot
Nuvectis Pharma, Inc. - COM (NVCT) Institutional Ownership
CUSIP: 67080T108
13F Institutional Holders and Ownership History from Q1 2022 to Q1 2026
Institutions Reporting
62
Shares (Excl. Options)
4,519,840
Price
$7.73
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 4,519,840
- Total reported value
- $34,936,893
- Portfolio coverage rank
- 0%
- Share change
- +268,584
- Value change
- +$2,076,848
- Number of holders
- 62
- Security type / class
- Equity / COM
- Symbol
- NVCT on Nasdaq
- Reported price per share
- $11.65
- Price from insider filings
- $11.65
Latest holder snapshot
7 facts
Security identity
2 facts
Issuer context
2 facts
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- NVCT - Nuvectis Pharma, Inc. - COM is tracked under CUSIP 67080T108.
- 62 institutions reported positions in Q1 2026.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 47 to 62 between Q4 2025 and Q1 2026.
- Reported value moved from $32,029,225 to $34,936,893.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 62 institutions filings for Q1 2026.
Security key
67080T108
Latest holder period
Q1 2026
13F holders
62
13D/G owners
0
CIK / CUSIP context first
Open Q1 2026 holders
NVCT full holder history
Nuvectis Pharma, Inc. SEC filings
Nuvectis Pharma, Inc. company facts
Nuvectis Pharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 67080T108:
As of 31 Mar 2026, 62 institutional investors reported holding 4,519,840 shares of Nuvectis Pharma, Inc. - COM (NVCT).
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
17
Latest
Q1 2026
Rows shown
1-17 of 17
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 4,519,840 | $34,936,893 | +$2,076,848 | $7.73 | 62 |
| 2025 Q4 | 4,238,693 | $32,029,225 | +$4,308,822 | $7.55 | 47 |
| 2025 Q3 | 3,694,801 | $22,240,671 | +$875,366 | $6.02 | 52 |
| 2025 Q2 | 3,242,656 | $24,212,274 | +$8,414,990 | $7.47 | 46 |
| 2025 Q1 | 2,047,125 | $20,049,463 | +$7,527,323 | $9.77 | 33 |
| 2024 Q4 | 1,320,778 | $7,145,290 | +$1,393,786 | $5.41 | 31 |
| 2024 Q3 | 1,049,389 | $6,599,330 | -$771,215 | $6.29 | 31 |
| 2024 Q2 | 1,205,075 | $7,627,698 | -$2,433,916 | $6.33 | 40 |
| 2024 Q1 | 1,561,977 | $12,807,385 | +$393,490 | $8.20 | 40 |
| 2023 Q4 | 1,513,319 | $12,620,464 | +$1,886,095 | $8.34 | 36 |
| 2023 Q3 | 1,277,304 | $16,463,587 | +$85,915 | $12.89 | 33 |
| 2023 Q2 | 1,252,927 | $20,033,227 | +$12,444,259 | $15.97 | 37 |
| 2023 Q1 | 483,928 | $6,343,634 | -$3,188,708 | $13.11 | 13 |
| 2022 Q4 | 983,925 | $7,378,970 | +$968,656 | $7.50 | 11 |
| 2022 Q3 | 1,417,003 | $10,047,000 | +$5,345,357 | $7.09 | 9 |
| 2022 Q2 | 643,014 | $7,201,000 | +$370,284 | $11.20 | 10 |
| 2022 Q1 | 628,110 | $4,654,000 | +$4,654,000 | $7.40 | 7 |